7/19/2013

Bethlehem, Pa.-based TB Biosciences has obtained $1.5 million in Series A financing, which will go toward the company's product-development activities and clinical studies. The company is working on a point-of-care assay for diagnosing tuberculosis using proteins found in people with active TB.

Related Summaries